Structure and catalytic mechanism of NADPH-cytochrome P450 oxidoreductase: A prototype of the diflavin oxidoreductase family of enzymes

Handbook of Flavoproteins: Complex Flavoproteins, Dehydrogenases and Physical Methods

Volumn 2, Issue , 2013, Pages 73-102

  Kim, Jung Ja P ^a   Shen, Anna L ^b   Xia, Chuanwu ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979159535     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1515/9783110298345.73     Document Type: Chapter

References (140)

1. Stuehr DJ, Tejero J, Haque MM. Structural and mechanistic aspects of flavoproteins: electron transfer through the nitric oxide synthase flavoprotein domain. FEBS J 2009;276:3959-74.
2. Daff S. NO synthase: structures and mechanisms. Nitric Oxide 2010;23:1-11.
3. Feng C. Mechanism of nitric oxide synthase regulation: electron transfer and interdomain interactions. Coord Chem Rev 2012;256:393-411.
4. Ruettinger RT, Wen LP, Fulco AJ. Coding nucleotide, 5' regulatory, and deduced amino acid sequences of P-450BM-3, a single peptide cytochrome P-450:NADPH-P-450 reductase from Bacillus megaterium. J Biol Chem 1989;264:10987-95.
5. Ostrowski J, Barber MJ, Rueger DC, Miller BE, Siegel LM, Kredich NM. Characterization of the flavoprotein moieties of NADPH-sulfite reductase from Salmonella typhimurium and Escherichia coli. Physicochemical and catalytic properties, amino acid sequence deduced from DNA sequence of cysJ, and comparison with NADPH-cytochrome P-450 reductase. J Biol Chem 1989;264:15796-808.
6. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, Heng HH, Rommens JM, Scherer SW, Rosenblatt DS, Gravel RA. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A 1998;95:3059-64.
7. Olteanu H, Banerjee, R. Human methionine synthase reductase, a soluble P450 reductaselike dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J Biol Chem 2001;276:35558-63.
8. Wolthers KR, Scrutton NS. Protein interactions in the human methionine synthase-methionine synthase reductase complex and implications for the mechanism of enzyme reactivation. Biochemistry 2007;46:6696-709.
9. Paine MJ, Garner AP, Powell D, Sibbald J, Sales M, Pratt N, Smith T, Tew, DG, Wolf CR. Cloning and characterization of a novel human dual flavin reductase. J Biol Chem 2000;275:1471-8.
10. Inui H, Yamaji R, Saidoh H, Miyatake K, Nakano Y, Kitaoka S. Pyruvate: NADP+ oxidore-ductase from Euglena gracilis: limited proteolysis of the enzyme with trypsin. Arch Biochem Biophys 1991;286:270-6.
11. Nakazawa M, Inui H, Yamaji R, Yamamoto T, Takenaka S, Ueda M, Nakano Y, Miyatake K. The origin of pyruvate: NADP+ oxidoreductase in mitochondria of Euglena gracilis. FEBS Lett 2000;479:155-6.
12. Netz DJ, StumpFig M, Dore C, Muhlenhoff U, Pierik AJ, Lill R. Tah18 transfers electrons to Dre2 in cytosolic iron-sulfur protein biogenesis. Nat Chem Biol 2010;6:758-65.
13. Schacter BA, Nelson EB, Marver HS, Masters BS. Immunochemical evidence for an association of heme oxygenase with the microsomal electron transport system. J Biol Chem 1972;247:3601-07.
14. Guengerich FP. Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. Arch Biochem Biophys 2005;440:12.
15. Ono T, Takahashi K, Odani S, Konno H, Imai, Y. Purification of squalene epoxidase from rat liver microsomes. Biochem Biophys Res Commun 1980;96:7.
16. Pearson JT, Siu S, Meininger DP, Wienkers LC, Rock DA. In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b(5) and methylene blue. Biochemistry 2010;49:10.
17. Petersen JA, Ebel RE, O'Keeffe DH, Matsubara T, Estabrook RW. Temperature dependence of cytochrome P-450 reduction. A model for NADPH-cytochrome P-450 reductase: cytochrome P-450 interaction. J Biol Chem 1976;251:7.
18. Shephard EA, Phillips IR, Bayney RM, Pike SF, Rabin BR. Quantification of NADPH: cytochrome P-450 reductase in liver microsomes by a specific radioimmunoassay technique. Biochem J 1983;211:8.
19. Johnson EF, Stout CD. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 2005;338:331-6.
20. Iyanagi T, Makino N, Mason HS. Redox properties of the reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 and reduced nicotinamide adenine dinucleotide-cytochrome b5 reductases. Biochemistry 1974;13:1701-10.
21. lyanagi T, Mason HS. Some properties of hepatic reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase. Biochemistry 1973;12:2297-308.
22. lyanagi T, Makina R, Anan FK. Studies on the microsomal mixed-function oxidase system: mechanism of action of hepatic NADPH-cytochrome P-450 reductase. Biochemistry 1981;20:1722-30.
23. Marcus RA, Sutin N. Biochim Biophys Acta 1985;811:265-322.
24. Chen HC, Swenson RP. Effect of the insertion of a glycine residue into the loop spanning residues 536-541 on the semiquinone state and redox properties of the flavin mononucleotide-binding domain of flavocytochrome P450BM-3 from Bacillus megaterium. Biochemistry 2008;47(52):13788-99.
25. Kasim M, Chen HC, Swenson RP. Functional characterization of the re-face loop spanning residues 536-541 and its interactions with the cofactor in the flavin mononucleotide-binding domain of flavocytochrome P450 from Bacillus megaterium. Biochemistry 2009;48:5131-41.
26. Das A, Grinkova YV, Sligar SG. Redox potential control by drug binding to cytochrome P450 3A4. J Am Chem Soc 2007;129:13778-9.
27. Brenner S, Hay S, Munro AW, Scrutton NS. Inter-flavin electron transfer in cytochrome P450 reductase - effects of solvent and pH identify hidden complexity in mechanism. FEBS J 2008;275:4540-57.
28. Munro AW, Noble MA, Robledo L, Daff SN, Chapman SK. Determination of the redox properties of human NADPH-cytochrome P450 reductase. Biochemistry 2001;40:1956-63.
29. Vermilion JL, Coon MJ. Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 1978;253(24):8812-9.
30. lyanagi T, Suzaki T, Kobayashi S. Oxidation-reduction states of pyridine nucleotide and cytochrome P-450 during mixed-function oxidation in perfused rat liver. J Biol Chem 1981;256:12933-9.
31. Yasukochi Y, Peterson JA, Masters BS. NADPH-cytochrome c (P-450) reductase. Spectropho-tometric and stopped flow kinetic studies on the formation of reduced flavoprotein intermediates. J Biol Chem 1979;254:7097-104.
32. Yamamoto K, Kimura S, Shiro Y, lyanagi T. Interflavin one-electron transfer in the inducible nitric oxide synthase reductase domain and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 2005;440:65-78.
33. Porter TD, Kasper CB. NADPH-cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins. Biochemistry 1986;25:1682-7.
34. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997;94:8411-6.
35. Karplus PA, Daniels MJ, Herriott JR. Atomic structure of ferredoxin-NADP+ reductase: prototype for a structurally novel flavoenzyme family. Science 1991;251:7.
36. Smith GC, Tew DG, Wolf CR. Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. Proc Natl Acad Sci U S A 1994;91:8710-4.
37. Hodgson AV, Strobel HW. Characterization of the FAD binding domain of cytochrome P450 reductase. Arch Biochem Biophys 1996;325:99-106.
38. Black SD, Coon MJ. Structural features of liver microsomal NADPH-cytochrome P-450 reductase. Hydrophobic domain, hydrophilic domain, and connecting region. J Biol Chem 1982;257:5929-38.
39. Porter TD, Kasper CB. Coding nucleotide sequence of rat NADPH-cytochrome P-450 oxi-doreductase cDNA and identification of flavin-binding domains. Proc Natl Acad Sci U S A 1985;82:973-7.
40. Taniguchi H, Imai Y, lyanagi T, Sato R. Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. Biochimica et biophysica acta 1979;550:341-56.
41. Black S, French JS, Williams JH, Jr, Coon MJ. Biochem Biophys Res Commun 1979;91:8.
42. Cojocaru V, Balali-Mood K, Sansom MS, Wade RC. Structure and dynamics of the membrane-bound cytochrome P4S0 2C9. PLoS Comput Biol 2012;7:e1002152.
43. Gilep A, Guryev OL, Usanov SA, Estabrook RW. An enzymatically active chimeric protein containing the hydrophilic form of NADPH-cytochrome P4S0 reductase fused to the membrane-binding domain of cytochrome bS. Biochem Biophys Res Commun 2001:5.
44. Venkateswarlu K, Lamb DC, Kelly DE, Manning NJ, Kelly SL. The N-terminal membrane domain of yeast NADPH-cytochrome P4S0 (CYP) oxidoreductase is not required for catalytic activity in sterol biosynthesis or in reconstitution of CYP activity. J Biol Chem 1998;273:5.
45. Das A, Sligar SG. Modulation of the cytochrome P4S0 reductase redox potential by the phospholipid bilayer. Biochemistry 2009;48:9.
46. Blanck J, Smettan G, Ristau O, Ingelman-Sundberg M, Ruckpaul K. Mechanism of rate control of the NADPH-dependent reduction of cytochrome P-450 by lipids in reconstituted phospholipid vesicles. Eur J Biochem 1984;144:5.
47. Vermilion JL, Ballou DP, Massey V, Coon MJ. Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 1981;256:266-77.
48. Shen AL, Porter T, Wilson TE, Kasper CB. Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J Biol Chem 1989;264(13):7584-9.
49. Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab Dispos 2010;38(2):332-40.
50. Nicolo C, Fluck CE, Mullis PE, Pandey AV. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol 2010;321(2):245-52.
51. Hamdane D, Xia C, Im SC, Zhang H, Kim JJ, Waskell L. Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J Biol Chem 2009;284:11374-84.
52. Bridges A, Gruenke L, Chang YT, Vakser IA, Loew G, Waskell L. Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J Biol Chem 1998;273:17036-49.
53. Im SC, Waskell L. The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b(5). Arch Biochem Biophys 2011;507:144-53.
54. Johnson EF. The 2002 Bernard B. Brodie Award lecture: deciphering substrate recognition by drug-metabolizing cytochromes P450. Drug Metab Dispos 2003;31:1532-40.
55. Nisimoto Y. Localization of cytochrome c-binding domain on NADPH-cytochrome P-450 reductase. J Biol Chem 1986;261:14232-9.
56. Nisimoto Y, Otsuka-Murakami H. Cytochrome b5, cytochrome c, cytochrome P-450 interactions with NADPHcytochrome P-450 reductase in phospholipid vesicles. Biochemistry 1988;27:5869-76.
57. Shen AL, Kasper CB. Role of acidic residues in the interaction of NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and cytochrome c. J Biol Chem 1995; 270(46):27475-80.
58. nd ed. Cytochrome P450: Structure, Mechamisn, and Biochemistry, ed. PR. Ortiz Montellano:1995, Plenum Press, New York.
59. Jang HH, Jamakhandi AP, Sullivan SZ, Yun CH, Hollenberg PF, Miller GP. Beta sheet 2-alpha helix C loop of cytochrome P450 reductase serves as a docking site for redox partners. Biochimica Biophysica Acta 2010;1804:9.
60. Hlavica P, Schulze J, Lewis DFV. Functional interaction of cytochrome P450 with its redox partners: a critical assessment and update of the topology of predicted contact regions. J Inorg Biochem 2003;96:19.
61. Zhao Q, Modi S, Smith G, Paine M, McDonagh PD, Wolf CR, Tew D, Lian LY, Roberts GC, Driessen HP. Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci 1999;8:298-306.
62. Bumpus NN, Hollenberg PF. Cross-linking of human cytochrome P450 2B6 to NADPH-cyto chrome P450 reductase: Identification of a potential site of interaction. J Inorg Biochem 2010;104:4.
63. Kenaan C, Zhang H, Shea EV, Hollenberg PF. Uncovering the role of hydrophobic residues in cytochrome P450-cytochrome P450 reductase interactions. Biochemistry 2011;50:3957-67.
64. Miwa GT, West SB, Huang MT, Lu AY. Studies on the association of cytochrome P-450 and NADPHcytochrome c reductase during catalysis in a reconstituted hydroxylating system. J Biol Chem 1979;254:5695-700.
65. Backes WL, Kelley RW. Organization of multiple cytochrome P450s with NADPH-cyto-chrome P450 reductase in membranes. Pharmacol Ther 2003;98:221-33.
66. Jamakhandi AP, Kuzmic P, Sanders DE, Miller GP. Global analysis of protein-protein interactions reveals multiple CYP2E1-reductase complexes. Biochemistry 2007;46:10192-201.
67. Kurzban GP, Strobel HW. Purification of flavin mononucleotide-dependent and flavin-ade-nine dinucleotide-dependent reduced nicotinamide-adenine dinucleotide phosphate-cyto-chrome P-450 reductase by high-performance liquid chromatography on hydroxyapatite. J Chromatogr 1986;358:296-301.
68. Narayanasami R, Nishimura JS, McMillan K, Roman LJ, Shea TM, Robida AM, Horowitz PM, Masters BS. The influence of chaotropic reagents on neuronal nitric oxide synthase and its flavoprotein module. Urea and guanidine hydrochloride stimulate NADPH-cytochrome c reductase activity of both proteins. Nitric Oxide 1997;1:39-49.
69. Narayanasami R, Horowitz PM, Masters BS. Flavin-binding and protein structural integrity studies on NADPH-cytochrome P450 reductase are consistent with the presence of distinct domains. Arch Biochem Biophys 1995;316:267-74.
70. Shen AL, Kasper CB. Differential contributions of NADPH-cytochrome P450 oxidoreductase FAD binding site residues to flavin binding and catalysis. J Biol Chem 2000;275:41087-91.
71. Zhang H, Gruenke L, Arscott D, Shen A, Kasper C, Harris DL, Glavanovich M, Johnson R, Waskell L. Determination of the rate of reduction of oxyferrous cytochrome P450 2B4 by 5-deazariboflavin adenine dinucleotide T491V cytochrome P450 reductase. Biochemistry 2003;42:6804-13.
72. Shen AL, Kasper CB. Role of Ser457 of NADPH-cytochrome P450 oxidoreductase in catalysis and control of FAD oxidation-reduction potential. Biochemistry 1996;35:9451-9.
73. Shen AL, Sem DS, Kasper CB. Mechanistic studies on the reductive half-reaction of NADPH-cytochrome P450 oxidoreductase. J Biol Chem 1999;274:5391-8.
74. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001;276:29163-70.
75. Deng Z, Aliverti A, Zanetti G, Arakaki AK, Ottado J, Orellano EG, Calcaterra NB, Ceccarelli EA, Carrillo N, Karplus PA. A productive NADP+ binding mode of ferredoxin-NADP+ reductase revealed by protein engineering and crystallographic studies. Nat Struct Biol 1999;6:847-53.
76. Tejero J, Perez-Dorado I, Maya C, Martinez-Julvez M, Sanz-Aparicio J, Gomez-Moreno C, Hermoso JA, Medina M. C-terminal tyrosine of ferredoxin-NADP+ reductase in hydride transfer processes with NAD(P)+/H. Biochemistry 2005;44:13477-90.
77. Sem DS, Kasper CB. Interaction with arginine 597 of NADPH-cytochrome P-450 oxidoreductase is a primary source of the uniform binding energy used to discriminate between NADPH and NADH. Biochemistry 1993;32:11548-58.
78. Gutierrez A, Doehr O, Paine M, Wolf CR, Scrutton NS, Roberts GC. Trp-676 facilitates nicotinamide coenzyme exchange in the reductive half-reaction of human cytochrome P450 reductase: properties of the soluble W676H and W676A mutant reductases. Biochemistry 2000;39:15990-9.
79. Elmore CL, Porter TD. Modification of the nucleotide cofactor-binding site of cytochrome P-450 reductase to enhance turnover with NADH in vivo. J Biol Chem 2002;277:48960-4.
80. Xia C, Hamdane D, Shen AL, Choi V, Kasper CB, Pearl NM, Zhang H, Im SC, Waskell L, Kim JJ. Conformational changes of NADPH-cytochrome P450 oxidoreductase are essential for catalysis and cofactor binding. J Biol Chem 2011;286:16246-60.
81. Xia C, Panda SP, Marohnic CC, Martasek P, Masters BS, Kim JJ. Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc Natl Acad Sci U S A 2011; 108:13486-91.
82. Page CC, Moser CC, Chen X, Dutton PL. Natural engineering principles of electron tunnelling in biological oxidation-reduction. Nature 1999;402:47-52.
83. Bhattacharyya AK, Lipka JJ, Waskell L, Tollin G. Laser flash photolysis studies of the reduction kinetics of NADPH: cytochrome P-450 reductase. Biochemistry 1991;30:759-65.
84. Gutierrez A, Paine M, Wolf CR, Scrutton NS, Roberts GC. Relaxation kinetics of cytochrome P450 reductase: internal electron transfer is limited by conformational change and regulated by coenzyme binding. Biochemistry 2002;41:4626-37.
85. Sem DS, Kasper CB. Effect of ionic strength on the kinetic mechanism and relative rate limitation of steps in the model NADPH-cytochrome P450 oxidoreductase reaction with cytochrome c._Biochemistry 1995;34:12768-74.
86. Sevrioukova IF, Li H, Zhang H, Peterson JA, Poulos TL. Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci U S A 1999;96:1863-8.
87. Gunsalus IC, Pederson TC, Sligar SG. Oxygenase-catalyzed biological hydroxylations. Ann Rev Biochem 1975;44:377-407.
88. Denisov IG, Makris TM, Sligar SG, Schlichting I. Structure and chemistry of cytochrome P450. Chem Rev 2005;105:2253-77.
89. Schlichting I, Chu K. Trapping intermediates in the crystal: ligand binding to myoglobin. Cur Opin Struct Biol 2000;10:744-52.
90. Kikuchi G, Yoshida T, Noguchi M. Heme oxygenase and heme degradation. Biochem Biophy Res Commun 2005;338:558-67.
91. Guengerich FP. Rate-limiting steps in cytochrome P450 catalysis. Biol Chem 2002;383: 1553-64.
92. Oprian DD, Vatsis KP, Coon MJ. Kinetics of reduction of cytochrome P-450LM4 in a reconstituted liver microsomal enzyme system. J Biol Chem 1979;254:8895-902.
93. Imai Y, Sato R, Iyanagi T. Rate-limiting step in the reconstituted microsomal drug hydroxylase system. J Biochem 1977;82:1237-46.
94. Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB, Henderson CJ, Wolf CR. Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J Biol Chem 2008;283:31385-93.
95. Yamazaki H, Johnson WW, Ueng YF, Shimada T, Guengerich FP. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. J Biol Chem 1996;271:27438-44.
96. Porter TD. The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol 2002;16:311-6.
97. Zhang H, Hamdane D, Im SC, Waskell L. Cytochrome b5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J Biol Chem 2008; 238:5217-25.
98. Chen Z, Banerjee R. Purification of soluble cytochrome b5 as a component of the reductive activation of porcine methionine synthase. J Biol Chem 1998;273:26248-55.
99. Marohnic CC, Huber WJ III, Patrick Connick J, Reed JR, McCammon K, Panda SP, Martasek P, Backes WL, Masters BS. Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization. Arch Biochem Biophys 2011;513(1):42-50.
100. Pandey AV, Fluck CE, Mullis PE. Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase. Biochem Biophy Res Commun 2010;400:374-8.
101. Li L, Porter TD. Hepatic cytochrome P450 reductase-null mice reveal a second microsomal reductase for squalene monooxygenase. Arch Biochem Biophys 2007;461:9.
102. Lamb DC, Kim Y, Yermalitskaya LV, Yermalitsky VN, Lepesheva GI, Kelly SL, Waterman MR, Podust LM. A second FMN binding site in yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron transfer by diflavin reductases. Structure 2006;14:51-61.
103. Gruez A, Pignol D, Zeghouf M, Coves J, Fontecave M, Ferrer JL, Fontecilla-Camps JC. Four crystal structures of the 60 kDa flavoprotein monomer of the sulfite reductase indicate a disordered flavodoxin-like module. J Mol Biol 2000;299:199-212.
104. Aigrain L, Pompon D, Morera S, Truan G. Structure of the open conformation of a functional chimeric NADPH cytochrome P450 reductase. EMBO Rep 2009;10:742-7.
105. Hay S, Brenner S, Khara B, Quinn AM, Rigby SE, Scrutton NS. Nature of the energy landscape for gated electron transfer in a dynamic redox protein. J Am Chem Soc 2010;132: 9738-45.
106. Ellis J, Gutierrez A, Barsukov IL, Huang WC, Grossmann JG, Roberts GC. Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering. J Biol Chem 2009;284:36628-37.
107. Vincent B, Morellet N, Fatemi F, Aigrain L, Truan G, Guittet E, Lescop E. The closed and compact domain organization of the 70-kDa human cytochrome P450 reductase in its oxidized state as revealed by NMR. J Mol Biol 2012;420:296-309.
108. Pudney CR, Khara B, Johannissen LO, Scrutton NS. Coupled motions direct electrons along human microsomal P450 Chains. pLOS Biology 2011;Dec 9, e1001222.
109. Guengerich FP, Cheng Q. Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol Rev 2011;63(3): 684-99.
110. Flück CE, Pandey AV. Clinical and biochemical consequences of p450 oxidoreductase deficiency. Endocrine development 2011;20:63-79.
111. Niedenthal R, Riles L, Guldener U, Klein S, Johnston M, Hegemann J. Systematic analysis of S. cerevisiae chromosome VIII genes. Yeast 1999;15:1775-96.
112. Benenati G, Penkov S, Müller-Reichert T, Entchev EV, Kurzchalia TV. Two cytochrome P450s in Caenorhabditis elegans are essential for the organization of eggshell, correct execution of meiosis and the polarization of embryo. Mechanisms of development 2009;126:382-93.
113. Rapp l eye CA, Tagawa A, Le Bot N, Ahringer J, Aroian RV. Involvement of fatty acid pathways and cortical interaction of the pronuclear complex in Caenorhabditis elegans embryonic polarity. BMC developmental biology 2003;Oct 3;3:8.
114. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002;277:6536-41.
115. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, Adams RH, Tickle C, Wolf CR. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003;23:6103-16.
116. Gu J, Cui H, Behr M, Zhang L, Zhang QY, Yang W, Hinson JA, Ding X. In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol Pharm 2005;67:623-30.
117. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, Yang W, Zhang L, Ding X. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003;278:25895-901.
118. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003;278:13480-6.
119. Stiborova M, Arlt VM, Henderson CJ, Wolf CR, Kotrbova V, Moserova M, Hudecek J, Phillips DH, Frei E. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug el-lipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharm 2008;226:318-27.
120. Weng Y, Fang C, Turesky RJ, Behr M, Kaminsky L, Ding X. Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res 2007;67:7825-32.
121. Wu L, Gu J, Cui H, Zhang QY, Behr M, Fang C, Weng Y, Kluetzman K, Swiatek PJ, Yang W, Kaminsky L, Ding X. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 2005;312:35-43.
122. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonça BB, Fujieda K, Miller WL. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36(3):228-30.
123. Fukami MHR, Nagai T, Tanaka T, Naiki Y, Sato N, Okuyama T, Nakai H, Soneda S, Tachibana K, Matsuo N, Sato S, Homma K, Nishimura G, Hasegawa T, Ogata T. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocr Metab 2005;90(1):414-26.
124. Antley R, Bixler D. Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 1975;11:397-401.
125. Yanagibashi K, Hall PF. Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem 1986;261:8429-33.
126. Lin D, Black SM, Nagahama Y, Miller WL. Steroid 17 alpha-hydroxylase and 17,20- I yase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 1993;132:2498-506.
127. Tee MK, Huang N, Damm I, Miller WL. Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. Mol Endocrinol 2011;25(5):715-31.
128. Soneda S, Yazawa T, Fukami M, Adachi M, Mizota M, Fujieda K, Miyamoto K, Ogata T. Proximal promoter of the cytochrome P450 oxidoreductase gene: identification of microdeletions involving the untranslated exon 1 and critical function of the SP1 binding sites. J Clin Endocrinol and Metab 2011;96:E1881-7.
129. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Fluck CE, Miller WL. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005;76:729-49.
130. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 2006;281(47):35975-82.
131. Hart SNWS, Nakamoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cyto chrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenetics and genomics 2008;18(1):11-24.
132. Gomes AM, Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, Zanger UM. Pharma-cogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009;10(4):579-99.
133. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 2008;105:1733-8.
134. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenetics and genomics 2008;569-76.
135. Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenetics and genomics 2010;20:611-8.
136. Sandee D, Morrissey K, Agrawal V, Tam, HK, Kramer MA, Tracy TS, Giacomini KM, Miller WL. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenomics 2010;20:677-86.
137. Subramanian M, Agrawal V, Sandee D, Tam, HK, Miller WL, Tracy TS. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CY-P2C9.2, and CYP2C9.3. Pharmacogenetics and genomics 2012;22:590-7.
138. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011;12:1281-91.
139. Garcin ED, Bruns CM, Lloyd SJ, Hosfield DJ, Tiso M, Gachhui R, Stuehr DJ, Tainer JA, Getzoff ED. Structural basis for isozyme-specific regulation of electron transfer in nitric-oxide synthase. J Biol Chem 2004;279:3791.
140. Iyanagi T, Xia C, Kim J-JP. NADPH-cytochrome P450 oxidoreductase: Prototypic member of the diflavin reductase family. Arch Biochem Biophys 2012; 528:72-89.